ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
2013
Recent trials have presented compelling evidence for the safety and efficacy of the new oral anticoagulants (NOACs) versus warfarin for stroke prevention in patients with atrial fibrillation (AF). The ENGAGE AF-TIMI 48 trial, the biggest of these trials, aims to evaluate the use of the direct factor Xa inhibitor, edoxaban.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
11
References
5
Citations
NaN
KQI